← Back to Search

Loop Diuretic

Bumetanide Injection for Heart Failure (MsDR Trial)

N/A
Recruiting
Led By Jeffrey Testani
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age > 18 years
No plan for titration/change of heart failure medical or device therapies during the study period
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 1 hour post bumetanide infusion.
Awards & highlights

MsDR Trial Summary

This trial will study the effects of different doses of a diuretic drug on patients with heart failure who are resistant or responsive to the drug.

Who is the study for?
This trial is for adults over 18 with heart failure who are stable on their current medications and haven't been hospitalized in the last 3 months. They should not have severe kidney issues, be using certain diuretics, or have conditions like restrictive cardiomyopathy. Pregnant or breastfeeding individuals and those unable to follow the study plan are excluded.Check my eligibility
What is being tested?
The study tests how well different doses of Bumetanide Injection work in patients with heart failure. It's a controlled experiment where each patient receives multiple doses in random order without knowing which dose they're getting at any time.See study design
What are the potential side effects?
Bumetanide may cause dehydration, electrolyte imbalances (like low potassium), low blood pressure, dizziness, potential kidney problems, and could affect hearing.

MsDR Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am older than 18 years.
Select...
I am not planning to change my heart failure treatments during the study.
Select...
I have been diagnosed with heart failure.
Select...
I am at my ideal body fluid level, as confirmed by my symptoms and doctor's exam.
Select...
I haven't been hospitalized unexpectedly in the last 3 months.

MsDR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in distal sodium reabsorption pre-diuretic to 1-hour post IV bumetanide infusion
Change in fractional excretion of lithium(FELi) pre-diuretic to 1-hour post IV bumetanide infusion
Ratio of A to F splice variant Messenger Ribonucleic Acid (mRNA )in urinary extracellular vesicles at baseline
+1 more

MsDR Trial Design

4Treatment groups
Active Control
Group I: Bumetanide 2.5 mgActive Control1 Intervention
2.5 mg Randomized to doses 10 mg, 5 mg, 2.5 mg, 1.25 mg
Group II: Bumetanide 1.25 mgActive Control1 Intervention
1.25 mg Randomized to doses 10 mg, 5 mg, 2.5 mg, 1.25 mg
Group III: Bumetanide 10 mgActive Control1 Intervention
Randomized to doses 10 mg, 5 mg, 2.5 mg, 1.25 mg
Group IV: Bumetanide 5 mgActive Control1 Intervention
5 mg Randomized to doses 10 mg, 5 mg, 2.5 mg, 1.25 mg

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,847 Previous Clinical Trials
2,736,453 Total Patients Enrolled
32 Trials studying Heart Failure
55,924 Patients Enrolled for Heart Failure
Jeffrey TestaniPrincipal InvestigatorYale University
1 Previous Clinical Trials
50 Total Patients Enrolled
1 Trials studying Heart Failure
50 Patients Enrolled for Heart Failure
Katherine KeithPrincipal InvestigatorYale University

Media Library

Bumetanide Injection (Loop Diuretic) Clinical Trial Eligibility Overview. Trial Name: NCT05323487 — N/A
Heart Failure Research Study Groups: Bumetanide 2.5 mg, Bumetanide 1.25 mg, Bumetanide 10 mg, Bumetanide 5 mg
Heart Failure Clinical Trial 2023: Bumetanide Injection Highlights & Side Effects. Trial Name: NCT05323487 — N/A
Bumetanide Injection (Loop Diuretic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05323487 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current enrollment size for this clinical trial?

"Affirmative. Clinicaltrials.gov lists this trial as actively recruiting, having been initially posted on June 1st 2022 and recently updated September 22nd 2022. As of now, the researchers are looking for 75 participants from a single site."

Answered by AI

Are there still vacancies available for patient participation in this clinical trial?

"Indeed, clinicaltrials.gov states that this clinical trial is currently enrolling participants. It was initially posted on June 1st 2022 and modified for the last time on September 22nd 2022. 75 volunteers are required from one medical facility."

Answered by AI

Who else is applying?

What state do they live in?
Connecticut
What site did they apply to?
Yale University
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
3+

Why did patients apply to this trial?

~38 spots leftby May 2026